CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
弥漫大 B 细胞淋巴瘤的免疫靶向治疗
英文原题：Immune targeted therapy for diffuse large B cell lymphoma.
查看英文原题
Immune targeted therapy for diffuse large B cell lymphoma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
弥漫大B细胞淋巴瘤（DLBCL）是非霍奇金淋巴瘤中最常见的亚型，具有高度异质性和侵袭性。尽管大多数DLBCL患者对利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗反应良好，但仍有约三分之一的患者预后较差。许多免疫靶向药物，如双特异性T细胞衔接器和CAR-T 细胞疗法，已被证明对难治性和复发性患者有效。本文综述了DLBCL免疫靶向治疗的研究进展。
展开英文摘要原文
Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, is highly heterogeneous and invasive. Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone treatment, approximately one-third of patients still have a poor prognosis.
Many immune-targeted drugs, such as bispecific T-cell engagers and CAR T-cell therapy, have been proven effective for refractory and relapsed patients. This article reviews the progress of immune targeted therapy for DLBCL.
论文信息
- 作者
- Zheng Y、Si J、Yuan T、Ding S、Tian C
- 单位
- Department of Hematology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China.China
- 文献类型
- 综述
- 期刊
- Blood science (Baltimore, Md.)2021 Oct
- 原文标识
- PubMed 35402846 · DOI 10.1097/BS9.0000000000000095
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →